• Channels
    • All News
    • Premium Content
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Law
    • Manufacturing
    • Marketing
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

Yesterday
R&D
In Focus

Sci­en­tists are fi­nal­ly learn­ing how to de­sign pro­teins from scratch. Drug de­vel­op­ment may nev­er be the same

Last week
People
Discovery

Ex­clu­sive: No­vo Nordisk al­lies it­self with one of the buzzi­est groups in biotech, launch­ing a mul­ti-pronged at­tack at dis­cov­er­ing new drugs

3 weeks ago
Deals
R&D

Is this Sil­i­con Val­ley duo the fu­ture of biotech?

3 weeks ago
People
AI

Con­gress mulls soft­er ac­cel­er­at­ed ap­proval re­forms as part of user fee reau­tho­riza­tions

3 weeks ago
R&D

Still-in-stealth biotech part­ners with Sloan Ket­ter­ing sci­en­tists to make per­son­al­ized can­cer ther­a­py more ‘pub­lic’

4 weeks ago
Discovery
Cell/Gene Tx

As Bio­gen hunts for a turn­around CEO, ex­ecs sketch out a hazy look at an un­cer­tain new fu­ture

4 weeks ago
Deals
Bioregnum

The R&D chal­lenge: 4 top drug hunters talk best prac­tices in build­ing a biotech to­day

4 weeks ago
R&D

Gilead joins a line­up of Big Phar­ma part­ners bet­ting big on TriN­KETs, with a $300M cash ante to get start­ed on a 5T4

4 weeks ago
Deals
Bioregnum

Arie and Dan Bellde­grun are build­ing biotech cam­pus­es around the globe — with a new­ly raised $3B fund to keep the dirt fly­ing

4 weeks ago
Financing

Aviv Regev re­cruits a ‘pur­ple uni­corn’ for the top post in the com­pu­ta­tion­al pil­lar she’s build­ing at Genen­tech

4 weeks ago
Bioregnum
Pharma

Can this tick bi­ol­o­gist and her team of ‘weirdo sci­ence’ en­thu­si­asts change the fu­ture of sci­en­tif­ic re­search?

5 weeks ago
People
Discovery

Scoop: Bridge­Bio's chief strat­e­gy of­fi­cer re­signs as the com­pa­ny qui­et­ly em­barks on an­oth­er round of lay­offs

5 weeks ago
R&D

The End­points R&D 15: How many block­busters does $124B buy the biggest spenders in drug re­search? (Not enough)

5 weeks ago
Special
Pharma

New pa­per sheds fresh light on Tmu­ni­ty's high-pro­file CAR-T deaths

Last month
R&D
Cell/Gene Tx

The 20(+1) un­der 40: Your guide to the next gen­er­a­tion of biotech lead­ers

Last month
Special

Guest col­umn: What hap­pened with Es­pe­ri­on — and what de­fines suc­cess or fail­ure?

Last month
Biotech Voices

'Em­pa­thy and love were not shown’: The sto­ry be­hind Taysha’s lay­offs, one of dozens of biotechs suf­fer­ing this year’s bear mar­ket

Last month
Cell/Gene Tx
In Focus

Af­ter Covid-19 suc­cess, pa­tients with the world’s ‘most stig­ma­tized’ in­fec­tion push for their own Op­er­a­tion Warp Speed

Last month
In Focus

The good, the bad and lots of just plain old ug­ly: The Q1 num­bers are in

Last month

Chirps, chats and Club­hous­es: First-time biotech founders turn to so­cial me­dia for ad­vice, in­vestors and re­cruit­ment

Last month
Startups
In Focus

Ex­clu­sive: Fol­low­ing a se­vere set­back, Bridge­Bio brings out the bud­get axe to chop staff but keeps qui­et on the num­bers

Last month
Pharma

Sanofi R&D team ac­cel­er­ates block­buster de­vel­op­ment ef­forts — while cast­ing doubt on a heavy­weight ri­val’s plans

Last month
Bioregnum

In­side the race to make psy­che­delics 'main­stream med­i­ci­nes'

Last month
R&D
In Focus
1234 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Content
  • Don't Miss
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Law
  • Manufacturing
  • Marketing
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints Company 2022

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
Endpoints News

Log in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

ENDPOINTS MARKETING RX Tue at 2 PM ET

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET